GE Healthcare Technologies Inc (GEHC)
NASDAQ:GEHC
Gadobutrol, Mri Scan, Mangaciclanol, Also Known As Geh200486 Injection, 0.5 Mmol/Ml
Known Or Highly Suspected Central Nervous System (Cns) Lesion, Known Or Highly Suspected Body (Excluding Cns) Lesion
Phase II/III
Not Yet Recruiting
A Phase 2/3 Study on the Efficacy and Safety of Mangaciclanol for Contrast-Enhanced MRI of CNS or Body in Adult Patients
Feb 12, 2026
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does GE Healthcare Technologies Inc (GEHC) have in its pipeline
GEHC is currently developing the following drugs: Gadobutrol, Mri Scan, Mangaciclanol, Also Known As Geh200486 Injection, 0.5 Mmol/Ml, Contrast-Enhanced Ultrasound. These drug candidates are in various stages of clinical development as the company works toward FDA approval.